Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Awen Oncology Transparent

Awen Oncology joins Start Codon

We're pleased to announce that Awen Oncology has become part of the Start Codon portfolio.

Awen Oncology is a trailblazing therapeutics start-up that is drugging developmentally-silent oncogenic drivers with its advanced platform.

Their innovative platform addresses a significant unmet need in oncology by homing in on developmental and germline-specific genes that, while dormant in healthy somatic tissues, become aberrantly reactivated during the onset and progression of cancer.

The company's platform stands out for its capacity to identify and target these genes, which play a pivotal role in oncogenesis.

Find out more on the Portfolio area of our website: